Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on RVNC. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Barclays reduced their target price on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Finally, Mizuho reduced their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Revance Therapeutics has a consensus rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Stock Performance

Shares of NASDAQ RVNC opened at $3.65 on Monday. The company has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The firm’s fifty day moving average is $3.54 and its two-hundred day moving average is $4.44. Revance Therapeutics has a 52-week low of $2.30 and a 52-week high of $7.56.

Hedge Funds Weigh In On Revance Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Natixis bought a new position in Revance Therapeutics during the 4th quarter valued at about $31,000. Two Sigma Securities LLC bought a new position in Revance Therapeutics during the 4th quarter valued at about $35,000. Alpine Global Management LLC bought a new position in Revance Therapeutics during the 4th quarter valued at about $37,000. FORA Capital LLC bought a new position in Revance Therapeutics during the 3rd quarter valued at about $54,000. Finally, RPO LLC purchased a new stake in Revance Therapeutics in the 4th quarter valued at about $55,000. 97.70% of the stock is currently owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.